antioxidant/breast neoplasms

BACKGROUND 1. Field of the Invention The teachings provided herein are generally directed to methods of isolating and using a whole-saliva leech extract in the treatment of a subject. 2. Description of the Related Art The history of humans using leeches goes back several thousands of years, and

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OD DEVELOPMENT Not Applicable REFERENCE TO SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISC APPENDIX Not Applicable FIELD OF THE INVENTION The present invention generally relates to a method for treating hyperproliferative

BACKGROUND Oxygen-containing free radicals including, for example, hydrogen peroxide, singlet oxygen, peroxynitrite, and superoxide can occur in cells as part of the normal metabolism of nutrients. These reactive oxygen species can cause oxidative damage to sensitive cellular components. Their

BACKGROUND OF THE INVENTION Field of the Invention This invention relates to a use of micronutrient formulations to reduce the effects of radiation on humans. Description of the Related Art Ionizing radiation (X-rays and gamma rays) has proven to be a double-edged sword in clinical Medicine since

FIELD OF THE INVENTION This invention relates to the field of nutritional supplements. BACKGROUND OF THE INVENTION Phytosterols are fats that are present in all plants, including fruits and vegetables. Although structurally similar to cholesterol, the sterols synthesized by animals and plants differ

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel compound, in particular to an extract isolated and purified from Antrodia camphorata, and its use in inhibiting tumor growth. 2. The Prior Arts Antrodia camphorata (Niu Chang-Zhi) is also called

BACKGROUND OF THE INVENTION Fulvestrant is an estrogen receptor antagonist, which was approved in the United States in 2002 under the tradename FASLODEX.TM. for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen

BACKGROUND OF THE INVENTION Fulvestrant is an estrogen receptor antagonist, which was approved in the United States in 2002 under the tradename FASLODEX.TM. for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen